Clinical trials

Clinical trials

Clinical trials are the only means of access to the new medicines that are as yet unavailable on the market. At present, there are many incurable eye diseases and research into new techniques and drugs is needed to confirm their efficacy and set out on the path to treatment and cure.

From the outset, BMF’s team has undertaken clinical trials that enable us to research new treatments or new ways of using existing ones in order to cure diseases and rescue patients from vision loss. The BMF, together with the Institut de la Màcula, is currently working on several clinical trials.

Who can take part in these clinical trials?

The access of patients to clinical trials is defined by means of exhaustive assessment of the candidate’s profile and the confirmation that a set of eligibility criteria have been met in order to participate in the study and receive treatment. The medical team will use all this information before giving its final approval.

What are the benefits/risks of taking part in a trial?

Participation in a clinical trial offers patients a series of advantages: the new treatment gives them the chance to receive state-of-the-art medical care from experts. This is, for the time being, also the only means of access to new drugs which are not available to the general public.

Clinical trials are performed in accordance with strict ethical and scientific principles. We at the BMF apply national and international standards and policies in protection of the rights, safety and welfare of participants.

Do patients need to pay?

The patients chosen for clinical trials are not charged for treatment and therefore it is completely free of charge.

How long will the trial last?

The duration will depend on the trial in which patients participate. Generally, this will be between one and two years maximum.

Clinical trials recruiting

If you are interested in taking part in a clinical trial, please call Institut de la Màcula at +34 93 595 01 55 and we will assess whether you are eligible.